Can Fite BioPharma Stock Price

0.0101 (0.44%)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Can Fite BioPharma Ltd CANF AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0101 0.44% 2.3001 08:21:51
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
20 5,485 569,955 1.51 - 4.39
Last Trade Time Type Quantity Stock Price Currency
08:21:51 formt 200 $ 2.3001 USD

Can Fite BioPharma Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 39.54M 17.19M 17.19M $ 763.00k $ - -1.20 -5.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Can Fite BioPharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CANF Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.302.332.112.25312,5280.00010.0%
1 Month2.062.622.042.40804,3660.240111.66%
3 Months2.502.621.942.32413,382-0.1999-8.0%
6 Months1.844.391.692.702,335,0370.460125.01%
1 Year1.764.391.512.531,616,9850.540130.69%
3 Years1.258.87650.382.34830,2591.0584.01%
5 Years2.578.87650.382.30540,614-0.2699-10.5%

Can Fite BioPharma Description

Can Fite Biofarma Ltd is a clinical-stage biopharmaceutical company. The company is focused on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune inflammatory indications, oncology and liver diseases as well as sexual dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention. The company's pipeline drugs are synthetic, specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile.

Your Recent History
Can Fite B..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.